株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CountryFocus:シンガポールの医療・規制・医療費償還制度の状況

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

発行 GlobalData 商品コード 321243
出版日 ページ情報 英文 238 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
CountryFocus:シンガポールの医療・規制・医療費償還制度の状況 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore
出版日: 2014年11月28日 ページ情報: 英文 238 Pages
概要

シンガポールの人口は、平均余命の改善などの影響により、2008年には480万人、2013年には540万人と増加し続けています。それに合わせて、医薬品市場も2008年には4億8900万米ドル、2013年には7億6100万米ドル、その間の年平均成長率(CAGR)は9.3%、と拡大傾向が続いています。また、2014年の市場規模は7億7600万米ドル、2020年には8億7300万米ドル、2014〜2020年のCAGRは2.0%、と推計されています。一方、医療技術部門の生産高は2011年には43億シンガポールドル(34億米ドル)に達し、更に2015年には50億シンガポールドル(40億米ドル)にまで拡大する見通しです。政府の積極的な支援策や大学での活発な研究活動が、医療関連市場のプラス成長に貢献しています。

当レポートでは、シンガポールの医療関連市場の動向や、医療費償還制度およびその他の関連規制・制度について分析し、医薬品産業・医療装置産業の全体的構造・動向、医療費償還制度やその周辺の保険市場の動向、医療規制当局の構造や各種規制の概要、シンガポール経済・社会に関するマクロ的指標(医療インフラなど)、今後の市場機会と課題といった情報を取りまとめて、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 医薬品・医療機器市場の概要

  • 医薬品市場
    • 市場概要
    • 医薬品の輸出入
    • 供給チャネル
    • 市場の分類
    • 主な疾患分野
    • 主な参入企業
  • 医療装置市場
    • 市場概要
  • 市場の促進要因と障壁
    • 促進要因
    • 参入障壁

第4章 市場へのアクセス

  • 医療費償還・保険料支払者の状況
    • 医療制度の概要
    • 医療費償還プロセス
    • 保険事業者の概要
    • 医療費支出に対する患者負担の比率
    • 医療サービスの価格動向
    • 薬価政策
  • 規制状況
    • 規制当局の概要
    • 医薬品の市販承認過程
    • 新しい医療装置の承認過程
    • 医療機器の新製品の認証過程
    • 輸出入
    • 知的所有権
    • 治験関連の規制
    • 医薬品の広告に関する規制
    • 薬局関連の規制
    • ラベリング・包装に関する規制

第5章 国別分析

  • 政治的環境
    • 政治的構造
    • 現在の政治的環境に関する分析
    • 医療関連の政策的取り組み
  • 経済情勢
  • 経済指標
    • 国内総生産(GDP)
    • 国民総所得
    • インフレーション
    • 為替レート
    • 海外直接投資
    • 外貨準備金
    • 貿易収支
    • 政府の構造バランス
    • 国債発行総額
    • 主要産業
  • 人口統計
    • 人口
    • 教育および識字率
    • 就労状況
    • 疾患負荷
  • 医療インフラ
    • 医療設備
    • 医療パラメーター
    • 環境衛生
    • 医療人材
  • 医療費
    • 概要
    • 公共/民間部門のシェア
    • 医療費支出の主な内容
    • 医薬品の研究開発への支出額
  • 産業団体
  • 見本市

第6章 市場機会および課題

  • 市場機会
  • 課題

第7章 付録

図表一覧

目次
Product Code: GDHC0074CHR

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

Singapore's population grew from 4.8 million in 2008 to 5.4 million in 2013, mainly due to the increase in the life expectancy (DoS, 2014). The value of the pharmaceuticals market increased from $489m in 2008 to $761m in 2013 at a Compound Annual Growth Rate (CAGR) of 9.3%, and this value is expected to increase further from $776m in 2014 to $873m in 2020 at a CAGR of 2.0% (Tarn et al., 2008; DoS, 2014; EDB, 2014c). In 2011, the output of the medical technology sector was SGD4.3 billion ($3.4 billion), which is expected to increase to SGD5 billion ($4 billion) in 2015 (EDB, 2014a).

These positive growth trends can primarily be attributed to -

  • Government initiatives
  • Universal healthcare coverage

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes -

  • Overview of the pharmaceutical market including size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Haw Par Corporation, SciGen, Pfizer, Novartis and GlaxoSmithKline
  • Insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country's healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -

  • Develop business strategies by understanding the trends shaping and driving Singapore's healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect Singapore's healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in Singapore's healthcare market

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. GlobalData Report Guidance

3. Overview of Pharmaceutical and Medical Device Market

  • 3.1. Pharmaceutical Market
    • 3.1.1. Market Overview
    • 3.1.2. Pharmaceutical Exports and Imports
    • 3.1.3. Supply Channels
    • 3.1.4. Market Segments
    • 3.1.5. Overview of Major Disease Areas
    • 3.1.6. Major Players
  • 3.2. Medical Device Market
    • 3.2.1. Market Overview
  • 3.3. Market Drivers and Barriers
    • 3.3.1. Drivers
    • 3.3.2. Barriers

4. Market Access

  • 4.1. Reimbursement and Payer Landscape
    • 4.1.1. Overview of Healthcare System
    • 4.1.2. Reimbursement Process
    • 4.1.3. Overview of Insurance Providers
    • 4.1.4. Patient Share in Healthcare Spending
    • 4.1.5. Price Trends in the Healthcare Sector
    • 4.1.6. Pricing Policies
  • 4.2. Regulatory Landscape
    • 4.2.1. Overview of Regulatory Agencies
    • 4.2.2. Market Authorization Procedure for Pharmaceutical Products
    • 4.2.3. New Medical Device Approval Process
    • 4.2.4. Licensing Process for Pharmaceutical and Medical Device Manufacturing
    • 4.2.5. Exports and Imports
    • 4.2.6. Intellectual Property Rights
    • 4.2.7. Clinical Trial Regulations
    • 4.2.8. Pharmaceutical Advertising Regulations
    • 4.2.9. Pharmacy Regulations
    • 4.2.10. Labeling and Packaging Regulations

5. Country Analysis

  • 5.1. Political Environment
    • 5.1.1. Political Structure
    • 5.1.2. Analysis of Current Political Environment
    • 5.1.3. Healthcare Policy Initiatives
  • 5.2. Economic Landscape
  • 5.3. Economic Indicators
    • 5.3.1. Gross Domestic Product
    • 5.3.2. Gross National Income
    • 5.3.3. Inflation
    • 5.3.4. Currency Exchange Rate
    • 5.3.5. Foreign Direct Investment
    • 5.3.6. Foreign Exchange Reserves
    • 5.3.7. Trade Balance
    • 5.3.8. Government Structural Balance
    • 5.3.9. Government Gross Debt
    • 5.3.10. Major Industries
  • 5.4. Demographics
    • 5.4.1. Population
    • 5.4.2. Education and Literacy
    • 5.4.3. Employment
    • 5.4.4. Disease Burden
  • 5.5. Healthcare Infrastructure
    • 5.5.1. Healthcare Facilities
    • 5.5.2. Healthcare Parameters
    • 5.5.3. Environmental Health
    • 5.5.4. Healthcare Personnel
  • 5.6. Healthcare Expenditure
    • 5.6.1. Overview
    • 5.6.2. Share of Public and Private Sectors
    • 5.6.3. Major Components of Healthcare Spending
    • 5.6.4. Spending in Pharmaceutical Research and Development
  • 5.7. Trade Associations
    • 5.7.1. The Singapore Association of Pharmaceutical Industries
    • 5.7.2. The Singapore Medical Association
    • 5.7.3. The Society for Emergency Medicine in Singapore
    • 5.7.4. The Pharmaceutical Society of Singapore
    • 5.7.5. The Healthcare Quality Society of Singapore
  • 5.8. Trade Fairs

6. Opportunities and Challenges

  • 6.1. Opportunities
  • 6.2. Challenges

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Bibliography
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Forecasts
    • 7.3.4. Expert Panel
  • 7.4. Disclaimer

List of Tables

  • Table 1: Pharmaceutical Market, Singapore, Revenue ($m), 2008-2013
  • Table 2: Pharmaceutical Market, Singapore, Revenue Forecast ($m), 2014-2020
  • Table 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2008-2013
  • Table 4: Pharmaceutical Market, Haw Par, Global, Major Products, 2014
  • Table 5: Pharmaceutical Market, SciGen, Global, Major Products, 2014
  • Table 6: Pharmaceutical Market, Pfizer, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
  • Table 7: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2014
  • Table 8: Pharmaceutical Market, Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
  • Table 9: Pharmaceutical Market, Novartis, Global, Planned Filings, 2014-2018
  • Table 10: Pharmaceutical Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
  • Table 11: Pharmaceutical Market, GlaxoSmithKline, Global, Late-Stage Pipeline, 2014
  • Table 12: Market Access, Singapore, Medisave Wage Contribution (%), 2014
  • Table 13: Market Access, Singapore, MediShield Premium Payment Scheme by Age Group ($), 2014
  • Table 14: Market Access, Singapore, Medisave-Approved Integrated Shield Plans Withdrawal Limit by Age Group ($), 2014
  • Table 15: Market Access, Singapore, Healthcare Spending, Out-of-Pocket Expenditure (%), 2008-2013
  • Table 16: Market Access, Singapore, Price of Pharmaceutical Products, Change in Average Price of Medicines (%), 2008-2013
  • Table 17: Market Access, Singapore, Registration Dossier Format, 2014
  • Table 18: Market Access, Singapore, Registration Dossier Format, 2014
  • Table 19: Market Access, Singapore, Registration Dossier Format, 2014
  • Table 20: Market Access, Singapore, GMP Certificate Fees for Medicinal Products and APIs ($), 2014
  • Table 21: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2014
  • Table 22: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2014
  • Table 23: Market Access, Singapore, Wholesale Dealer's License Fees for Medicinal Products ($), 2014
  • Table 24: Market Access, Singapore, Patent Co-operation Treaty (PCT), International Application Process, 2014
  • Table 25: Market Access, Singapore, Patent Filing Fees and Charges SGD ($), 2014
  • Table 26: Market Access, Singapore, Clinical Trial Certificates Issued, 2008-2013
  • Table 27: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2013
  • Table 28: Market Access, Singapore, Target Processing Timelines of Clinical Trial, 2014
  • Table 29: Market Access, Singapore, Fees for Advertisement Permit ($), 2010
  • Table 30: Market Access, Singapore, Fees for Advertisement Permit ($), 2014
  • Table 31: Market Access, Singapore, Labeling Requirements, 2014
  • Table 32: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), 2008-2013
  • Table 33: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), Forecast, 2014-2020
  • Table 34: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), 2008-2013
  • Table 35: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), Forecast, 2014-2020
  • Table 36: Economic Indicators, Singapore, Gross National Income per Capita ($), 2008-2013
  • Table 37: Economic Indicators, Singapore, Consumer Price Index, 2008-2013
  • Table 38: Economic Indicators, Singapore, Average Consumer Price Index, Forecast, 2014-2020
  • Table 39: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2008-2013
  • Table 40: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), Forecast, 2014-2020
  • Table 41: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2008-2013
  • Table 42: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2008-2013
  • Table 43: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2008-2013
  • Table 44: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2008-2013
  • Table 45: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2008-2013
  • Table 46: Economic Indicators, Singapore, General Government Structural Balance ($bn), 2008-2013
  • Table 47: Economic Indicators, Singapore, General Government Gross Debt ($bn), 2008-2013
  • Table 48: Economic Indicators, Singapore, Major Industries, Industrial Sector, Gross Value Added ($bn), 2012-2013
  • Table 49: Demographics, Singapore, Population (million), 2008-2013
  • Table 50: Demographics, Singapore, Population Forecast (million), 2014-2020
  • Table 51: Demographics, Singapore, Population Distribution by Age Group (%), 2008-2013
  • Table 52: Demographics, Singapore, Population Distribution by Age Group Forecast (%), 2014-2020
  • Table 53: Demographics, Singapore, Births (per 1,000 Population), 2008-2013
  • Table 54: Demographics, Singapore, Mortality (per 1,000 Population), 2008-2013
  • Table 55: Demographics, Singapore, Major Causes of Mortality ('000), 2008
  • Table 56: Demographics, Singapore, Children Under Five Mortality Rate (per 1,000 Live Births), 2008-2013
  • Table 57: Demographics, Singapore, Immunization Rate (%), 2008-2013
  • Table 58: Demographics, Singapore, Major Causes of Male Mortality (per 1,000 Population), 2008
  • Table 59: Demographics, Singapore, Major Causes of Female Mortality (per 1,000 Population), 2008
  • Table 60: Demographics, Singapore, Gender Ratio (M/F), 2008-2013
  • Table 61: Demographics, Singapore, Life Expectancy at Birth (Years), 2008-2013
  • Table 62: Demographics, Singapore, Student Enrollment by Level of Education (%), 2013
  • Table 63: Demographics, Singapore, Unemployment Rate (%), 2008-2013
  • Table 64: Demographics, Singapore, Major Causes of Patient Discharge (%), 2012
  • Table 65: Demographics, Singapore, Major Diseases, DALYs (per 100,000 Population), 2004
  • Table 66: Healthcare Infrastructure, Singapore, Hospitals, 2008-2013
  • Table 67: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2008-2013
  • Table 68: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 Population), 2008-2013
  • Table 69: Healthcare Infrastructure, Singapore, Beds by Type of Hospital, 2008-2013
  • Table 70: Healthcare Infrastructure, Singapore, Number of Physicians (per 10,000 Population), 2008-2013
  • Table 71: Healthcare Infrastructure, Singapore, PM10 (µg/m³), 2008-2013
  • Table 72: Healthcare Infrastructure, Singapore, CO2 Emissions (Million Metric Tons), 2008-2013
  • Table 73: Healthcare Infrastructure, Singapore, Water Pollutants (Million Metric Tons), 2008-2013
  • Table 74: Healthcare Infrastructure, Singapore, Waste Generated (million Tons), 2008-2013
  • Table 75: Healthcare Infrastructure, Singapore, Waste Handling Methods Share (%), 2013
  • Table 76: Healthcare Infrastructure, Singapore, Waste Recycling Share by Type of Waste (%), 2013
  • Table 77: Healthcare Infrastructure, Singapore, Nurses (per 1,000 Population), 2008-2013
  • Table 78: Healthcare Infrastructure, Singapore, Midwives (per 1,000 Population), 2008-2013
  • Table 79: Healthcare Infrastructure, Singapore, Dentists (per 1,000 Population), 2008-2013
  • Table 80: Healthcare Infrastructure, Singapore, Pharmacists (per 1,000 Population), 2008-2013
  • Table 81: Healthcare Infrastructure, Singapore, Healthcare Expenditure (% of GDP), 2008-2013
  • Table 82: Healthcare Infrastructure, Singapore, Public-Private Share (%), 2008-2013
  • Table 83: Healthcare Infrastructure, Singapore, Share of Expenditure of Major Components of Healthcare Spending (%), 2014
  • Table 84: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2008-2013
  • Table 85: Trade Fairs, Singapore, Major Healthcare Trade Fairs, 2014

List of Figures

  • Figure 1: Pharmaceutical Market, Singapore, Revenue ($m), 2008-2013
  • Figure 2: Pharmaceutical Market, Singapore, Revenue Forecast ($m), 2014-2020
  • Figure 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2008-2013
  • Figure 4: Pharmaceutical Market, Singapore, Distribution Channels, 2014
  • Figure 5: Healthcare Market, Singapore, Drivers and Barriers, 2014
  • Figure 6: Market Access, Singapore, Healthcare Insurance System, 2014
  • Figure 7: Market Access, Singapore, Healthcare Financing System, 2014
  • Figure 8: Market Access, Singapore, Healthcare Spending, Out-of-Pocket Expenditure (%), 2008-2013
  • Figure 9: Market Access, Singapore, Price of Pharmaceutical Products, Change in Average Price of Medicines (%), 2008-2013
  • Figure 10: Market Access, Singapore, Structure of the Ministry of Health, 2014
  • Figure 11: Market Access, Singapore, Structure of the Health Sciences Authority, 2014
  • Figure 12: Market Access, Singapore, New Drug Application Types, 2014
  • Figure 13: Market Access, Singapore, New Drug Approval Process, 2014
  • Figure 14: Market Access, Singapore, Licensing Process for Manufacturing, 2014
  • Figure 15: Market Access, Singapore, Licensing Process for Import/Export, 2014
  • Figure 16: Market Access, Singapore, National Patent Approval Process, 2014
  • Figure 17: Market Access, Singapore, PCT National Phase Entry Process, 2014
  • Figure 18: Market Access, Singapore, International Patent Approval Process, 2014
  • Figure 19: Market Access, Singapore, National Trademark Approval Process, 2014
  • Figure 20: Market Access, Singapore, International Trademark Approval Process, 2014
  • Figure 21: Market Access, Singapore, Clinical Trial Certificates Issued, 2008-2013
  • Figure 22: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2013
  • Figure 23: Market Access, Singapore, Clinical Trial Approval Process, 2014
  • Figure 24: Market Access, Singapore, Pharmacy Regulations, 2014
  • Figure 25: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), 2008-2013
  • Figure 26: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), Forecast, 2014-2020
  • Figure 27: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), 2008-2013
  • Figure 28: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), Forecast, 2014-2020
  • Figure 29: Economic Indicators, Singapore, Gross National Income per Capita ($), 2008-2013
  • Figure 30: Economic Indicators, Singapore, Consumer Price Index, 2008-2013
  • Figure 31: Economic Indicators, Singapore, Average Consumer Price Index, Forecast, 2014-2020
  • Figure 32: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2008-2013
  • Figure 33: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), Forecast, 2014-2020
  • Figure 34: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2008-2013
  • Figure 35: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2008-2013
  • Figure 36: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2008-2013
  • Figure 37: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2008-2013
  • Figure 38: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2008-2013
  • Figure 39: Economic Indicators, Singapore, Government Structural Balance ($bn), 2008-2013
  • Figure 40: Economic Indicators, Singapore, General Government Gross Debt ($bn), 2008-2013
  • Figure 41: Economic Indicators, Singapore, Major Industries, Industrial Sector, Gross Value Added ($bn), 2012-2013
  • Figure 42: Demographics, Singapore, Population (million), 2008-2013
  • Figure 43: Demographics, Singapore, Population Forecast (million), 2014-2020
  • Figure 44: Demographics, Singapore, Population Distribution by Age Group (%), 2008-2013
  • Figure 45: Demographics, Singapore, Population Distribution by Age Group Forecast (%), 2014-2020
  • Figure 46: Demographics, Singapore, Births (per 1,000 Population), 2008-2013
  • Figure 47: Demographics, Singapore, Mortality (per 1,000 Population), 2008-2013
  • Figure 48: Demographics, Singapore, Major Causes of Mortality ('000), 2008
  • Figure 49: Demographics, Singapore, Children Under Five, Mortality Rate (per 1,000 Live Births), 2008-2013
  • Figure 50: Demographics, Singapore, Immunization Rate (%), 2008-2013
  • Figure 51: Demographics, Singapore, Major Causes of Male Mortality (per 1,000 Population), 2008
  • Figure 52: Demographics, Singapore, Major Causes of Female Mortality (per 1,000 Population), 2008
  • Figure 53: Demographics, Singapore, Gender Ratio (M/F), 2008-2013
  • Figure 54: Demographics, Singapore, Life Expectancy at Birth (Years), 2008-2013
  • Figure 55: Demographics, Singapore, Student Enrollment by Level of Education (%), 2013
  • Figure 56: Demographics, Singapore, Unemployment Rate (%), 2008-2013
  • Figure 57: Demographics, Singapore, Major Causes of Patient Discharge (%), 2012
  • Figure 58: Demographics, Singapore, Major Diseases, DALYs (per 100,000 Population), 2004
  • Figure 59: Healthcare Infrastructure, Singapore, Hospitals, 2008-2013
  • Figure 60: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2008-2013
  • Figure 61: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 Population), 2008-2013
  • Figure 62: Healthcare Infrastructure, Singapore, Beds by Type of Hospital, 2008-2013
  • Figure 63: Healthcare Infrastructure, Singapore, Number of Physicians (per 10,000 Population), 2008-2013
  • Figure 64: Healthcare Infrastructure, Singapore, PM10 (µg/m³), 2008-2013
  • Figure 65: Healthcare Infrastructure, Singapore, CO2 Emissions (Million Metric Tons), 2008-2013
  • Figure 66: Healthcare Infrastructure, Singapore, Water Pollutants (Million Metric Tons), 2008-2013
  • Figure 67: Healthcare Infrastructure, Singapore, Waste Generated (million Tons), 2008-2013
  • Figure 68: Healthcare Infrastructure, Singapore, Waste Handling Methods Share (%), 2013
  • Figure 69: Healthcare Infrastructure, Singapore, Waste Recycling Share by Type of Waste (%), 2013
  • Figure 70: Healthcare Infrastructure, Singapore, Nurses (per 1,000 Population), 2008-2013
  • Figure 71: Healthcare Infrastructure, Singapore, Midwives (per 1,000 Population), 2008-2013
  • Figure 72: Healthcare Infrastructure, Singapore, Dentists (per 1,000 Population), 2008-2013
  • Figure 73: Healthcare Infrastructure, Singapore, Pharmacists (per 1,000 Population), 2008-2013
  • Figure 74: Healthcare Infrastructure, Singapore, Healthcare Expenditure (% of GDP), 2008-2013
  • Figure 75: Healthcare Infrastructure, Singapore, Public-Private Share (%), 2008-2013
  • Figure 76: Healthcare Infrastructure, Singapore, Share of Expenditure of Major Components of Healthcare Spending (%), 2014
  • Figure 77: Healthcare Infrastructure, Singapore, R&D Expenditure ($m), 2008-2013
  • Figure 78: Healthcare Market, Singapore, Opportunities and Challenges, 2014
Back to Top